Prevalence of primary sclerosing cholangitis (PSC) in Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders: systematic review and meta-analysis

阅读:1

Abstract

AIM: To evaluate the prevalence of primary sclerosing cholangitis (PSC) among Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders. BACKGROUND: PSC is a rare and chronic liver disease characterized by inflammation, fibrosis, and intra- and/or extrahepatic bile duct structure. METHODS: A systematic review and meta-analysis was conducted. The Web of Science, Scopus, Pubmed, Embase, Google Scholar, and local databases, including the IranDoc, IranMedex, SID, and MagIran databases, were searched for studies published before 6th February 2023 for the prevalence of PSC among Iranian adults. RESULTS: In total, 22 articles involving 19,747 Iranian participants were included in this meta-analysis. The overall pooled prevalence of PSC was 8% (95% CI: 5%-12%). Additionally, the prevalence of PSC stratified by gender was calculated based on four studies (n = 1402). The pooled prevalence of PSC was estimated to be 20% (95% CI: 11-31%) in males and 12% (95% CI: 3-38%) in females. The pooled prevalence of PSC was 6% (95% CI: 4-9%) in patients with IBD and 14% (95% CI: 8-23%) in patients with liver transplantation (LT). CONCLUSION: The pooled prevalence of PSC was 8% in Iranian adults, and the prevalence was greater in males than in females.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。